NHS Logo

Oncology: Genomics, Precision Medicine and Therapeutic Targets (Record no. 103586)

MARC details
000 -LEADER
fixed length control field 04143nam a22004815i 4500
001 - CONTROL NUMBER
control field 978-981-99-1529-3
003 - CONTROL NUMBER IDENTIFIER
control field DE-He213
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20240729140111.0
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION
fixed length control field cr nn 008mamaa
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 230630s2023 si | s |||| 0|eng d
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
ISBN 9789819915293
-- 978-981-99-1529-3
072 #7 - SUBJECT CATEGORY CODE
Subject category code MJCL
Source bicssc
072 #7 - SUBJECT CATEGORY CODE
Subject category code MED062000
Source bisacsh
072 #7 - SUBJECT CATEGORY CODE
Subject category code MJCL
Source thema
245 10 - TITLE STATEMENT
Title Oncology: Genomics, Precision Medicine and Therapeutic Targets
250 ## - EDITION
Edition statement 1st ed. 2023.
264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE
Place of production, publication, distribution, manufacture Singapore :
Name of producer, publisher, distributor, manufacturer Springer Nature Singapore :
-- Imprint: Springer,
Date of production, publication, distribution, manufacture, or copyright notice 2023.
300 ## - PHYSICAL DESCRIPTION
Physical description XVI, 274 p. 23 illus., 15 illus. in color.
Other physical details online resource.
336 ## - CONTENT TYPE
Content type term text
Content type code txt
Source rdacontent
337 ## - MEDIA TYPE
Media type term computer
Media type code c
Source rdamedia
338 ## - CARRIER TYPE
Carrier type term online resource
Carrier type code cr
Source rdacarrier
505 0# - CONTENTS
Contents Chapter 1 Evolution of translational cancer therapeutics -- Chapter 2 Oncology: Way forward from clinical and molecular diagnosis to treatment -- Chapter 3 Oncogenic genomics alterations in cancer patient -- Chapter 4 Altered mRNA expression profiles in cancer patients -- Chapter 5 microRNAs and long non-coding RNAs as key targets -- Chapter 6 Oncogenic alterations translated into diagnostics -- Chapter 7 Precision medicine in oncology -- Chapter 8 Precision medicine - translation of individualistic treatment in oncology -- Chapter 9Pharmacogenetics and Pharmacogenomics in Precision Medicine -- Chapter 10 Pharmacogenetic factors in pharmacodynamic/pharmacokinetic (PD/PK) modulations of medicines -- Chapter 11 Biomarkers in Precision Medicine in oncology -- Chapter 12 Bioinformatics and biostatistics in Precision Medicine -- Chapter 13 Omics in Precision medicine -- Chapter 14 Translational therapeutic targets : from bench to clinical trials -- Chapter 15 Strength of integartive genomic alterations, precision medicine and therapeutic targets as treatment choice in patient care.
520 ## - ABSTRACT
Abstract This book describes translational cancer therapeutics and the way forward from clinical and molecular diagnosis to treatment. In addition, genomics alterations, microRNAs, and long non-coding RNAs translate precision medicine for the individualistic therapy of cancer patients. It describes the involvement of various pharmacogenetic factors in pharmacodynamic/pharmacokinetic (PD/PK) modulations of medicines. Indeed, the role of bioinformatics and biostatistics, considering the extensive data analysis serving precision medicine approaches, has also been entertained in the present book. Therefore, intended book demonstrates the successful medical evidence for the use of precision medicine in the treatment of cancer and its future clinical perspectives. It fills the gaps in cancer biology and precision medicine with its up-to-date content and well-designed chapters. It will serve as a valuable resource for science, medical students, and interdisciplinary researchers. It is a very welcome addition for the scientific community, research centers, and university-industry research collaborators to find out a complete capsular package about cancer drug targets, precision, and personalized medicine (including an introduction to cancer cell signaling, genomic alterations, miRNA targeting, pharmacogenetics, biomarkers, and metabolomics in precision medicine, etc.) at a single platform.
650 #0 - SUBJECT HEADINGS
Subject term Cancer.
650 #0 - SUBJECT HEADINGS
Subject term Cancer
General subdivision Genetic aspects.
650 #0 - SUBJECT HEADINGS
Subject term Oncology.
9 (RLIN) 13364
650 #0 - SUBJECT HEADINGS
Subject term Therapeutics.
650 14 - SUBJECT HEADINGS
Subject term Cancer Biology.
650 24 - SUBJECT HEADINGS
Subject term Cancer Genetics and Genomics.
650 24 - SUBJECT HEADINGS
Subject term Oncology.
9 (RLIN) 13364
650 24 - SUBJECT HEADINGS
Subject term Therapeutics.
700 1# - ADDED PERSONAL NAME
Added personal author Tuli, Hardeep Singh.
Relator term editor.
700 1# - ADDED PERSONAL NAME
Added personal author Yerer Aycan, M�kerrem Bet�l.
Relator term editor.
710 2# - ADDED CORPORATE NAME
Added corporate author SpringerLink (Online service)
856 ## - ONLINE RESOURCE
Uniform Resource Identifier <a href="#gotoholdings">#gotoholdings</a>
Link text Access resource
245 ## - TITLE STATEMENT
Medium [E-Book]
347 ## - DIGITAL FILE CHARACTERISTICS
File type text file
Encoding format PDF
Source rda
912 ## -
-- ZDB-2-SBL
912 ## -
-- ZDB-2-SXB
Holdings
Withdrawn status Lost status Damaged status Not for loan Home library Current library Shelving location Date acquired Source of acquisition Total Checkouts Date last seen Uniform Resource Identifier Price effective from Koha item type
        Hillingdon Hospitals Library Services (Hillingdon Hospitals NHS Foundation) Hillingdon Hospitals Library Services (Hillingdon Hospitals NHS Foundation) Online 02/05/2024 Springer BiomedLifeSc_2023   02/05/2024 https://go.openathens.net/redirector/nhs?url=https://doi.org/10.1007/978-981-99-1529-3 02/05/2024 Electronic book
London Health Libraries Consortium Privacy notice and Membership terms and conditions